Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | GLA | P06280 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | CASP1 | P29466 | 2/20 | 1.00 |
| ▸ | CASP7 | P55210 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | MAOA | P21397 | 1/20 | 0.94 |
| ▸ | MAOB | P27338 | 3/20 | 0.63 |
| ▸ | STS | P08842 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | PDE2A | O00408 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30465069 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL3625077 | 0.98 | CYP1A2 (1.00) | KDM4EALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL3762769 | 0.98 | CYP1A2 (1.00) | KDM4EALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL3757463 | 0.97 | MAOA (1.00) | KDM4EALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL10793789 | 0.87 | ALDH1A1 (0.77) | KDM4EALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL10791718 | 0.85 | CYP1A2 (0.77) | KDM4EALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL10795665 | 0.83 | KDM4E (0.70) | KDM4EALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL10790036 | 0.83 | KDM4E (0.70) | KDM4EALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL10789263 | 0.83 | MAOA (0.77) | KDM4EALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL9336449 | 0.83 | KDM4E (0.71) | KDM4EALDH1A1HPGDHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2023-11-21 | — | — | US | disclosed |
| CN-116178330-A | Fluorescent probe, synthesis method and application | 湖北大学 | 2023-05-30 | — | — | CN | disclosed |
| EP-2958906-A1 | 3-SUBSTITUTED-6H-BENZO[C]CHROMEN-6-ONES AND 3-SUBSTITUTED-7,8,9,10-TETRAHYDRO-6H-BENZO[C]CHROMEN-6-ONES AGAINST SENILE DEMENTIA | Nobel Ilaç Sanayii Ve Ticaret A.S. (TR) | 2015-12-30 | — | — | EP | disclosed |
| WO-2014129989-A1 | 3-SUBSTITUTED-6H-BENZO[C]CHROMEN-6-ONES AND 3-SUBSTITUTED-7,8,9,10-TETRAHYDRO-6H-BENZO[C]CHROMEN-6-ONES AGAINST SENILE DEMENTIA | FARGEM FARMASÖTİK ARAŞTIRMA GELİŞTİRME MERKEZİ SANAYİ VE TİCARET A.Ş. (TR) | 2014-08-28 | — | — | WO | disclosed |
| WO-2014129989-A1 | 3-SUBSTITUTED-6H-BENZO[C]CHROMEN-6-ONES AND 3-SUBSTITUTED-7,8,9,10-TETRAHYDRO-6H-BENZO[C]CHROMEN-6-ONES AGAINST SENILE DEMENTIA | FARGEM FARMASÖTİK ARAŞTIRMA GELİŞTİRME MERKEZİ SANAYİ VE TİCARET A.Ş. (TR) | 2014-08-28 | — | — | WO | disclosed |
| US-7846965-B2 | a non-steroidal sulphamate compound such as 6-Oxo-8,9,10,11-tetrahydro-7H-cyclohepta-[c][1]benzopyran-3-O-sulphamate, suitable for use as an inhibitor of estrone sulphatase, for the treatment of endocrine-dependent cancers and tumors, such as the breast and endometrium | STERIX LIMITED (GB) | 2010-12-07 | — | — | US | disclosed |
| EP-1957475-A1 | CHROMENONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merz Pharma GmbH & Co.KGaA (DE) | 2008-08-20 | — | — | EP | disclosed |
| US-20070173531-A1 | Compound | REED MICHAEL J | 2007-07-26 | — | — | US | disclosed |
| WO-2007045876-A1 | CHROMENONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045876-A1 | CHROMENONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-04-26 | — | — | WO | disclosed |
| US-4681954-A | 7,8,9,10-tetrahydro-6-oxo-6H-dibenzo(b,d)pyranyloxy-propanes | PENNWALT CORPORATION (US) | 1987-07-21 | — | — | US | disclosed |
| EP-0221293-A1 | 7,8,9,10-Tetrahydro-6-oxo-6H-dibenzo[b,d]pyranyloxy-propanes | PENNWALT CORPORATION (US) | 1987-05-13 | — | — | EP | disclosed |
| EP-0218195-A2 | Bis(dibenzo[b,d]pyranyloxy)propanes | PENNWALT CORPORATION (US) | 1987-04-15 | — | — | EP | disclosed |
| US-4647674-A | Bis-(dibenzo[b,d]pyranyloxy) propanes | PENNWALT CORPORATION (US) | 1987-03-03 | — | — | US | disclosed |
| US-4618622-A | ANTIDEPRESSANTS, ANTIALLERGENS | BASF AKTIENGESELLSCHAFT (DE) | 1986-10-21 | — | — | US | disclosed |
| US-4569994-A | Dibenzo[b,d]pyranyloxyaminopropanols | PENNWALT CORPORATION | 1986-02-11 | — | — | US | disclosed |
| EP-0043535-B1 | TRICYCLIC ARYLIC ETHERS, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 1984-10-31 | — | — | EP | disclosed |
| EP-0111746-A2 | Sulfonic-acid esters of hydroxycoumarines, their preparation and medicines containing them | BASF Aktiengesellschaft (DE) | 1984-06-27 | — | — | EP | disclosed |
| US-4382943-A | DIHYDROCYCLOPENTA/C//1/BENZOPYRAN-4-/1H/ONES | BOEHRINGER MANNHEIM GMBH (DE) | 1983-05-10 | — | — | US | disclosed |
| EP-0043535-A1 | Tricyclic arylic ethers, process for their preparation and medicines containing these compounds | Roche Diagnostics GmbH (DE) | 1982-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173531-A1 | Compound | HSD17B11, NR5A1, CYP17A1 | KDM4E 1129/4885ALDH1A1 611/4885HPGD 260/4885 |
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | KDM4E 4333/4885ALDH1A1 851/4885HPGD 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.